MDGL Q4 2023 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$117M

Net Income

-$112M

EPS (Diluted)

$-5.68

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$80M

Free Cash Flow

-$81M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$641M

Total Liabilities

$235M

Stockholders' Equity

$405M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$117M	-$85M	-37.4%
Net Income	-$112M	-$86M	-30.6%